Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lymphoma, Hodgkin lymphoma, child
Stage/Subtype:  stage III childhood Hodgkin lymphoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 44 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients With Lymphoma
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Phase: Phase III
Type: Treatment
Age: 65 and under
Trial IDs: CB-AB006, NCI-2013-00758, 2012-0166, NCT01854567
Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Hodgkin Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Supportive care, Treatment
Age: 18 and younger
Trial IDs: AHOD1331, NCI-2014-01223, NCT02166463
Autologous or Donor Cytotoxic T-Lymphocytes in Treating Patients with Epstein-Barr Virus-Positive Hematologic Malignancy
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: ALCI, NCI-2012-00653, 9936-ALCI, H-9936, NCT00070226, NCT00671164, NCT00062868
Conventional and Regulatory T Cells in Treating Patients With Advanced Hematologic Malignancies Undergoing T Cell-Depleted Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 13 to 60
Trial IDs: BMT236, NCI-2011-03025, NCT01660607
Gemcitabine Hydrochloride, Clofarabine, and Busulfan before Donor Stem Cell Transplant in Treating Patients with Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 65
Trial IDs: 2012-0506, NCI-2012-02055, NCT01701986
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients with Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 to 30
Trial IDs: AHOD1221, NCI-2013-00107, COG-AHOD1221, NCT01780662
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)
Phase: Phase II, Phase I
Type: Treatment
Age: 6 months to less than 18 years
Trial IDs: 3475-051, NCI-2015-00528, 2014-002950-38, NCT02332668
Low-Dose Chemotherapy, Low-Dose Total-Body Irradiation, and Anti-Thymocyte Globulin Followed By Donor Bone Marrow Transplant in Treating Patients With Hematologic Malignancy or Kidney Cancer
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2001-10, NCI-2010-02155, 2001LS058, UMN-2001LS058, UMN-MT2001-10, NCT00303719
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation and Anti Thymocyte Globulin before Umbilical Cord Blood Transplantation in Treating Patients with Hematological Cancer
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2005-02, NCI-2010-01415, 2005LS036, UMN-2005LS036, UMN-MT-2005-02, UMN-0507M70121, NCT00305682
Donor Stem Cell Transplant with Mismatched Donors and High-Dose Post-Transplant Cyclophosphamide in Treating Patients with Hematologic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 65
Trial IDs: 2009-0266, NCI-2011-03144, NCT01010217
Rasburicase or Allopurinol in Preventing Tumor Lysis Syndrome in Patients with Hematological Malignancies Undergoing Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2010-0284, NCI-2012-01889, NCI-2010-02082, NCT01200485
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Immune Therapy in Treating Patients with Epstein-Barr Virus Lymphoproliferative Disorders or Epstein-Barr Virus-Associated Malignancies
Phase: Phase II
Type: Diagnostic, Treatment
Age: any age
Trial IDs: 11-130, NCI-2012-00594, NCT01498484
Bulk or Fractionated Stem Cell Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II
Type: Treatment
Age: Under 75
Trial IDs: 12-016, NCI-2012-00824, NCT01596257
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
Phase: Phase II
Type: Treatment
Age: 15 to 55
Trial IDs: FT1050-03, NCI-2013-00116, NCT01627314
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low or Intermediate-Risk Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: H-30993, NCI-2013-01346, TXCH-HD-12A, NCT01858922
Safety Study of Cord Blood Units for Stem Cell Transplants
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093
Brentuximab Vedotin, Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients with Stage IIB-IVB Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and under
Trial IDs: HLHR13, NCI-2013-01123, NCT01920932
Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes in Treating Patients With Newly Diagnosed or Recurrent Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: CAR CD30, NCI-2012-00640, H-26617, NCT01192464
Start Over